Alport Syndrome clinical trials at University of California Health
1 in progress, 0 open to eligible people
Sorry, in progress, not accepting new patients
The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.
Our lead scientists for Alport Syndrome research studies include Niloofar Nobakht.